Professional Summary

Professional Overview

Phil Hammond is an accomplished biotechnology executive with extensive expertise in the areas of CMC (Chemistry, Manufacturing, and Controls) and biopharmaceutical development. As the Associate Vice President of CMC at TORL BioTherapeutics, LLC, he plays a crucial role in overseeing the company's manufacturing and quality control processes, ensuring the seamless progression of their therapeutic candidates through clinical trials and regulatory approvals.

Experience Summary

Current Role

As the Associate Vice President of CMC at TORL BioTherapeutics, LLC, Phil is responsible for leading the company's CMC strategy and operations. He oversees the development and implementation of robust manufacturing processes, analytical methods, and quality control systems to support the advancement of TORL's innovative biotherapeutics. Under his guidance, the company has streamlined its CMC operations, leading to accelerated timelines and improved success rates in regulatory submissions.

Career Progression

Prior to his current role, Phil served as the Senior Director of CMC at OncoResponse Inc., where he spearheaded the development and manufacturing of their oncology-focused biotherapeutics. Before that, he held the position of Director of CMC/Preclinical Development at Zymeworks Inc., where he played a pivotal role in advancing the company's bispecific antibody platform and securing multiple strategic partnerships.

Phil's career trajectory also includes entrepreneurial experience, as he founded and led sAber Bioscience, a start-up focused on developing novel biotherapeutic approaches. Additionally, he has held various scientific and leadership roles at Theraclone Sciences, Phylos, Mosaic Technologies, and Gen-Probe Antisense Therapeutics (later Chugai Biopharmaceuticals).

Academic Background

Phil holds a Ph.D. in Molecular Biology from the University of Colorado, where his research focused on the development of innovative therapeutic strategies. His academic achievements, combined with his extensive industry experience, have positioned him as a respected expert in the field of biopharmaceutical development.

Areas of Expertise

• Biopharmaceutical manufacturing and quality control

• Regulatory strategy and compliance

• Analytical method development and validation

• Upstream and downstream process optimization

• Project management and cross-functional collaboration

• Strategic planning and decision-making

Professional Impact

Throughout his career, Phil has made significant contributions to the biopharmaceutical industry. He has led the successful development and commercialization of several therapeutic candidates, with a track record of navigating complex regulatory landscapes and achieving regulatory approvals. Phil's expertise and leadership have been instrumental in driving innovation and advancing the field of biotherapeutics.

Conclusion

With his deep understanding of CMC processes, strong technical acumen, and proven track record of success, Phil Hammond is a highly valuable asset to TORL BioTherapeutics, LLC. As the Associate Vice President of CMC, he continues to drive the company's manufacturing and quality control strategies, contributing to the advancement of their promising biotherapeutic pipeline and positively impacting the lives of patients.